

Claims

1. Use of a complete antibody molecule specific for IL-13R α 1 having full length heavy and light chains with a VH sequence of SEQ ID NO: 51 and a VL sequence of SEQ ID NO: 53 in the manufacture of a medicament for treating an inflammatory disorder or an autoimmune disease in a human patient by inhibiting IL-13R α 1,
wherein the medicament is to be administered in multiple doses so as to maintain a C-trough level of the antibody molecule in serum between doses in the range of 0.5 to 10mg/L and thereby maintain a pharmacodynamic effect, and wherein each dose comprises 200 to 600 mg of the antibody molecule and is to be administered at least once each month.
2. The use according to claim 1, wherein the antibody molecule binds to the epitope FFYQ (SEQ ID NO: 64).
3. The use according to claim 1, wherein each dose comprises 300 mg of the antibody molecule.
4. The use according to claim 1, wherein each dose comprises 400 mg of the antibody molecule.
5. The use according to claim 1, wherein each dose comprises 600 mg of the antibody molecule.
6. The use according to claim 1, wherein the medicament is to be administered subcutaneously.
7. The use according to claim 1, wherein the medicament is to be administered not more than twice a month.
8. The use according to claim 1, wherein the medicament is to be administered once every 7 days or once a week.
9. The use according to claim 1, wherein the medicament is to be administered once every 2 weeks.
10. The use according to claim 1, wherein the medicament is to be administered once every 3 weeks.
11. The use according to claim 1, wherein the medicament is to be administered once every 4 weeks or once a month.
12. The use according to claim 1, wherein the full-length heavy chain has the amino acid sequence set forth in SEQ ID NO: 59.
13. The use according to claim 12, wherein the full-length light chain has the amino acid sequence set forth in SEQ ID NO: 62.
14. The use according to any one of claims 1 to 13, wherein the inflammatory disorder is atopic dermatitis.